Summary
Stryker Corporation's (SYK) second quarter and first half of 2011 results demonstrate a company navigating significant growth, driven by strategic acquisitions, while also managing increased operating expenses and integration costs. Net sales saw robust year-over-year growth, particularly in the Neurotechnology and Spine segment, largely propelled by the substantial acquisition of Boston Scientific's Neurovascular division. However, reported net earnings experienced a slight decline due to higher costs associated with these acquisitions, including inventory step-ups and integration expenses. The company's balance sheet reflects a significant increase in goodwill and other intangible assets, indicating its aggressive M&A strategy. Despite the impact of acquisition-related charges on reported earnings, the company's adjusted earnings per share showed strong growth, suggesting underlying operational strength. Investors should monitor the integration progress of recent acquisitions and the company's ability to translate these strategic moves into sustainable profitability. Furthermore, ongoing legal and tax matters, while not immediately impacting current financials, represent potential risks that warrant attention.
Financial Highlights
51 data points| Revenue | $2.05B |
| Cost of Revenue | $713.00M |
| Gross Profit | $1.33B |
| R&D Expenses | $114.00M |
| SG&A Expenses | $786.00M |
| Operating Expenses | $932.00M |
| Operating Income | $401.00M |
| Net Income | $309.00M |
| EPS (Basic) | $0.80 |
| EPS (Diluted) | $0.79 |
| Shares Outstanding (Basic) | 388.20M |
| Shares Outstanding (Diluted) | 392.00M |
Key Highlights
- 1Net sales increased by 16% in Q2 2011 and 14% in the first half of 2011 compared to the prior year periods, driven by strong performance in MedSurg and Neurotechnology and Spine segments.
- 2The acquisition of Boston Scientific's Neurovascular division for $1.45 billion and Orthovita for $316 million significantly boosted the Neurotechnology and Spine segment sales by 53% in Q2 and 51% in H1 2011.
- 3Reported net earnings decreased by 3% in Q2 and 4% in H1 2011, primarily due to acquisition and integration-related charges, including a $36.8 million inventory step-up in Q2.
- 4Adjusted diluted EPS grew by 13% in Q2 and 13% in H1 2011 (excluding acquisition-related charges), indicating solid underlying operational performance.
- 5Cash flow from operations decreased significantly, largely due to increased working capital needs, particularly higher inventory levels and cash paid for acquisitions.
- 6The company maintained a strong liquidity position with $497.1 million in cash and cash equivalents and $2,177.9 million in marketable securities at the end of Q2 2011.
- 7Stryker is actively managing its tax positions, having reached agreements with the IRS on certain income allocation matters, but faces ongoing assessments related to cost sharing arrangements.